Claims for Patent: 10,191,034

Summary for Patent: 10,191,034

Title:	Dosage regimen for administrating a CD19×CD3 bispecific antibody to patients at risk for potential adverse effects
Abstract:	A method for assessing the risk of potential adverse effects for a human patient receiving a CD19×CD3 bispecific antibody is provided. The method comprises determining the total B count in the patient, and identifying a B cell number indicative of a patient at risk of potential adverse effects from the antibody. The method further provides a dosing schedule for administering the antibody to the patient identified as at risk of potential adverse effects. Also provided is a pharmaceutical package or kit comprising a first dose and a second dose, and optionally a third dose, of the CD19×CD3 bispecific antibody as defined in the methods/dosage regimen of the disclosure.
Inventor(s):	Nagorsen Dirk
Assignee:	AMGEN RESEARCH (MUNICH) GMBH
Application Number:	US14113755
Patent Claims:

Details for Patent 10,191,034

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	December 03, 2014	10,191,034	2032-04-30

International Patent Family for US Patent 10,191,034

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012146394
United States of America	2019293635
United States of America	2014199307
United States of America	11579142
Mexico	354371
Mexico	2013012448
South Korea	20200104415